Haematology

The Department of Hematology currently has 69 beds, including 4 transplant beds. The department has 15 physicians, including 4 chief physicians and 4 deputy chief physicians. Five hold doctoral degrees, and several have undertaken advanced training abroad. The hematology nursing team has 19 nursing staff members, including 1 deputy chief nurse, 9 charge nurses, 6 nurse practitioners, and 2 nurses; among them, 1 holds a graduate degree and 18 hold bachelor’s degrees.

Academic leader: Zhong Yuping (钟玉萍), chief physician, Doctor of Medicine, professor, and a high-level talent recruited by Qingdao. She graduated from the Chinese Academy of Medical Sciences and Peking Union Medical College. From August 2004 to August 2020, she worked at Beijing Chaoyang Hospital, Capital Medical University. From 2012 to 2013, she was a senior visiting scholar at the University of Texas MD Anderson Cancer Center. She has also visited Mayo Clinic and the University of Cambridge for academic exchange and study. She was the principal author of, and participated in the development of, multiple professional guidelines. Research focus: diagnosis and treatment of lymphatic and plasma cell diseases. Academic appointments: national standing committee member of the Hematology Physicians Branch of the Chinese Medical Doctor Association; member of the Asian Myeloma Network (AMN); chair of the Plasma Cell Diseases Professional Committee of the Chinese Association for the Promotion of Human Health Science and Technology; member of the Plasma Cell Diseases Group of the Hematology Branch of the Chinese Medical Association; member of the Periodic Assessment Working Committee for Hematology Physicians of the Chinese Medical Doctor Association; and leader of the Plasma Cell Diseases Working Group of the Lymphoma Professional Committee of the Shandong Anti-Cancer Association. She has led and participated in multiple funded projects, published more than 50 articles, and contributed to two volumes of Multiple Myeloma published by the People’s Medical Publishing House.

The department is at the forefront in China in the diagnosis and treatment of plasma cell diseases and is aligned with international standards. It serves as the chairing institution of the Plasma Cell Diseases Professional Committee of the Chinese Association for the Promotion of Human Health Science and Technology, the lead institution of the Shandong Plasma Cell Working Group, the Jiaodong Peninsula Multiple Myeloma Medical and Research Center, the Amyloidosis Regional Collaboration Group, and other organizations. It integrates clinical care, teaching, and research. The department routinely performs hematopoietic stem cell transplantation, targeted therapy, immunotherapy, CAR-T cell therapy, and other cutting-edge treatments, including international and domestic multicenter clinical trials of novel drugs. It has accumulated extensive experience in the diagnosis and treatment of multiple myeloma, amyloidosis, lymphoma, leukemia, myelodysplastic syndrome (MDS), aplastic anemia, bleeding and coagulation disorders, and other hematologic diseases.

The department integrates clinical care, teaching, and research and has complete specialized facilities, including specialty wards such as general wards and laminar-flow clean wards, a multidisciplinary joint outpatient clinic, and disease-specific outpatient clinics for multiple myeloma, amyloidosis, lymphoma, and other conditions. It has accumulated extensive experience in the diagnosis and treatment of multiple myeloma, amyloidosis, POEMS, Castleman disease, lymphoma, various leukemias, myelodysplastic syndrome (MDS), aplastic anemia, bleeding and coagulation disorders, and other hematologic diseases. The department routinely performs hematopoietic stem cell transplantation, targeted therapy, immunotherapy, CAR-T cell therapy, and other cutting-edge treatments, including clinical trials of novel drugs.

Patients with the signature specialty condition, multiple myeloma, account for more than 50% of all inpatients. The department has become a regional medical center for this disease, demonstrating a strong specialty advantage. It established Qingdao’s first Amyloidosis Specialty Clinic, Amyloidosis MDT Clinic, and Multiple Myeloma Rehabilitation MDT Clinic. Autologous hematopoietic stem cell transplantation has proceeded smoothly; more than 50 cases have been performed to date, with a 100% success rate. In 2025, the department introduced the first commercially available CarT cell therapy for multiple myeloma in the Jiaodong Peninsula and is also undertaking multiple international and domestic multicenter clinical trials. Professor Zhong Yuping, the department director, was re-elected chair of the Plasma Cell Diseases Committee of the Chinese Association for the Promotion of Human Health Science and Technology and was successfully elected a standing committee member of the Hematology Physicians Branch of the Chinese Medical Doctor Association. She has participated in drafting multiple professional guidelines. The department hosted the Fourth Academic Symposium on Plasma Cell Diseases and the Fifth Qingdao Training Course on New Advances in Multiple Myeloma, a high-level national academic conference. It has hosted nearly 20 academic conferences of various sizes. Making full use of its specialty strengths and relying on the Plasma Cell Diseases Professional Committee of the Chinese Association for the Promotion of Human Health Science and Technology, the department’s Plasma Cell Practice Academy, operated as the chairing institution, has become a recognized brand in the field. It engages in exchanges with primary hospitals in various formats, including lectures, ward rounds, and discussions or reviews of difficult cases, enabling more primary-care physicians to participate, expanding the influence of the hospital and department, and providing training for primary-care physicians. The department actively responds to the national planning and policies for establishing regional medical centers and, relying on the professional committee, works to expand the market for disease-specific services. It continues to implement the 1+x Project, using the department as the lead to support hematology departments in several county- and city-level hospitals in establishing plasma cell disease subspecialty services, establishing an MDT model to improve the diagnosis and treatment of plasma cell diseases, and forming an Amyloidosis Collaboration Group to achieve earlier diagnosis of these diseases and improve patients’ quality of life and survival.

The department supervises 4 graduate students, regularly conducts teaching ward rounds and case discussions, and provides high-quality training for residents in standardized residency training. It has successfully completed all teaching tasks assigned by the hospital and was recognized by the hospital as a Teaching and Talent Development Brand Department. Since 2022, the department has published more than 20 articles and has received funding for 2 Qingdao Municipal Health Commission research projects and 1 national chronic disease research project.

Young physicians have been sent successively for advanced training to China’s leading hospitals, including Peking Union Medical College Hospital, Peking University People’s Hospital, and Peking University Third Hospital. The department’s medical and nursing staff have also participated in ward rounds led by Academician Huang Xiaojun. Young physicians are encouraged to attend national academic conferences and competitions, and one won first prize in a national hematology science-popularization competition. Every year, research from the department is accepted by the international conferences EHA and ASH for presentation and academic exchange.

Editing time: 2026/5/20 15:43:59